MFG-E8 Regulates Angiogenesis in Cutaneous Wound Healing

Our research group recently demonstrated that pericytes are major sources of the secreted glycoprotein and integrin ligand lactadherin (MFG-E8) in B16 melanoma tumors, and that MFG-E8 promotes angiogenesis via enhanced PDGF–PDGFRβ signaling mediated by integrin–growth factor receptor crosstalk. However, sources of MFG-E8 and its possible roles in skin physiology are not well characterized. The objective of this study was to characterize the involvement of MFG-E8 in skin wound healing. In the dermis of normal murine and human skin, accumulations of MFG-E8 were found around CD31+ blood vessels, and MFG-E8 colocalized with PDGFRβ+, αSMA+, and NG2+ pericytes. MFG-E8 protein and mRNA levels were elevated in the dermis during full-thickness wound healing in mice. MFG-E8 was diffusely present in granulation tissue and was localized around blood vessels. Wound healing was delayed in MFG-E8 knockout mice, compared with the wild type, and myofibroblast and vessel numbers in wound areas were significantly reduced in knockout mice. Inhibition of MFG-E8 production with siRNA attenuated the formation of capillary-like structures in vitro. Expression of MFG-E8 in fibrous human granulation tissue with scant blood vessels was less than that in granulation tissue with many blood vessels. These findings suggest that MFG-E8 promotes cutaneous wound healing by enhancing angiogenesis

Development of tinea corporis in a Japanese patient with atopic dermatitis under treatment with upadacitinib in a real‐world clinical setting: Possible contribution of the suppression of Th17

We present a rare case of a patient with AD who developed tinea corporis during upadacitinib treatment in a real‐world clinical setting. We hypothesized that the suppressive effect of Th17 immunity by upadacitinib possibly has contributed to the development of tinea corporis

A case of disseminated extranodal Rosai–Dorfman disease diagnosed by skin manifestations

Abstract Rosai–Dorfman disease (RDD) is a rare non‐Langerhans cell histiocytosis that was first described as sinus histiocytosis with massive lymphadenopathy by Rosai and Dorfman in 1969. While classical/nodal RDD is typical, extranodal involvement is seen in up to 43% of all cases, with 23% showing only extranodal lesions. Here, we present a case of disseminated extranodal RDD, where the initial symptoms were cutaneous manifestations

Geranium sibiricum L. var. glabrius Ohwi

原著和名: イチゲフウロ科名: フウロソウ科 = Geraniaceae採集地: 北海道 苫小牧市北部 (北海道 胆振 苫小牧北部)採集日: 1985/8/28採集者: 萩庭丈壽整理番号: JH026508国立科学博物館整理番号: TNS-VS-97650

Photo absorption coefficient of oxyhemoglobin and deoxyhemoglobin.

<p>Photo absorption coefficient of oxyhemoglobin and deoxyhemoglobin.</p

<i>ΔC</i>_<i>Hb</i> measured in four healthy volunteers and four scleroderma patients.

<p><i>ΔC</i>_<i>Hb</i> measured in four healthy volunteers and four scleroderma patients.</p

Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience

Abstract Objective Dupilumab has been deemed highly effective for atopic dermatitis (AD). However, there have been no reports performing a combination analysis with hematological data and improvement rates pertaining to the continued use of dupilumab for up to 2 years in real world. In this study, we evaluated the effectiveness and safety of using dupilumab for up to 2 years in 9 patients with AD at our hospital. Methods Thirty‐six patients with moderate‐to‐severe AD treated by dupilumab, and 9 of them treated for 2 years. Changes in the severity scoring, pruritus numerical rating scale (NRS), patient‐oriented eczema measure (POEM), serum levels of immunoglobulin E (IgE), thymus and activation‐regulated chemokine (TARC), eosinophils, and lactate dehydrogenase (LDH) at Week 0, 2, 4, 16, 48, 72, and 96 of those patients were investigated, and we studied features of the patients who had any adverse events (AEs). Results Investigator’s global assessment (IGA), eczema area and severity index (EASI), body surface area (BSA), NRS, POEM, and serum levels of LDH were significantly decreased from Week 4 onwards to Week 96 compared with baseline condition. Serum levels of TARC and LDH were significantly decreased from Week 4 onwards to Week 96. Regarding 9 patients who were treated with dupilumab for up to 2 years, serum levels of TARC and eosinophils decreased without statistical significance. The serum levels of IgE significantly decreased at Week 72, 96 compared with the baseline. Regarding as AEs, ocular symptoms were the most frequently observed (15/36, 41.2%), and there were no cases of discontinuation due to AEs. Conclusions Treatment with dupilumab was well tolerated and showed improvements in AD for at least 2 years